KR920011481A - N, n'-비스[3-(에틸아미노)프로필]-1, 7-헵탄디아민 및 세포독성제를 함유하는 암치료용 제약 조성물 - Google Patents

N, n'-비스[3-(에틸아미노)프로필]-1, 7-헵탄디아민 및 세포독성제를 함유하는 암치료용 제약 조성물 Download PDF

Info

Publication number
KR920011481A
KR920011481A KR1019910022757A KR910022757A KR920011481A KR 920011481 A KR920011481 A KR 920011481A KR 1019910022757 A KR1019910022757 A KR 1019910022757A KR 910022757 A KR910022757 A KR 910022757A KR 920011481 A KR920011481 A KR 920011481A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
cytotoxic agent
neoplastic
ethylamino
propyl
Prior art date
Application number
KR1019910022757A
Other languages
English (en)
Other versions
KR100195423B1 (ko
Inventor
제이. 프라캐쉬 넬리쿤자
엘. 보울린 테리
Original Assignee
스티븐 엘. 네스비트
메렐 다우 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 엘. 네스비트, 메렐 다우 파마슈티칼스 인크. filed Critical 스티븐 엘. 네스비트
Publication of KR920011481A publication Critical patent/KR920011481A/ko
Application granted granted Critical
Publication of KR100195423B1 publication Critical patent/KR100195423B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

N, N'-비스[3-(에틸아미노)프로필]-1, 7-헵탄디아민 및 세포독성제를 함유한 암치료용 제약 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 항신생물 유효량의 N, N'-비스[3-(에틸아미노)프로필]-1, 7-헵탄디아민 및 항신생물 빙카 알칼로이드, 항신생물 항생제, 항신생물 항대사물 및 항신생물 백금 배위 착체로 이루어진 군에서 선택된 항신생물 유효량의 세포독성제로 이루어진 신생물 질병 치료용 제약 조성물.
  2. 제1항에 있어서, 세포독성제가 빈블라스틴임을 특징으로 하는 제약 조성물.
  3. 제1항에 있어서, 세포독성제가 시스플라틴임을 특징으로 하는 제약 조성물.
  4. 제1항에 있어서, 세포독성제가 아드리아마이신임을 특징으로 하는 제약 조성물.
  5. 제1항에 있어서, 세포독성제가 시타라빈임을 특징으로 하는 제약 조성물.
  6. 제1항에 있어서, 신생물 질병이 백혈병임을 특징으로 하는 제약 조성물.
  7. 제1항에 있어서, 신생물 질병이 암(carcinoma)임을 특징으로 하는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910022757A 1990-12-13 1991-12-12 N,n'-비스(3-(에틸아미노)프로필)-1,7-헵탄디아민 및 세포독성제를 함유하는 암치료용 제약조성물 KR100195423B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62681490A 1990-12-13 1990-12-13
US626,814 1990-12-13

Publications (2)

Publication Number Publication Date
KR920011481A true KR920011481A (ko) 1992-07-24
KR100195423B1 KR100195423B1 (ko) 1999-06-15

Family

ID=24511975

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910022757A KR100195423B1 (ko) 1990-12-13 1991-12-12 N,n'-비스(3-(에틸아미노)프로필)-1,7-헵탄디아민 및 세포독성제를 함유하는 암치료용 제약조성물

Country Status (11)

Country Link
EP (1) EP0490380B1 (ko)
JP (1) JPH04275233A (ko)
KR (1) KR100195423B1 (ko)
AT (1) ATE163264T1 (ko)
AU (1) AU648846B2 (ko)
DE (1) DE69128926T2 (ko)
DK (1) DK0490380T3 (ko)
ES (1) ES2113870T3 (ko)
GR (1) GR3026432T3 (ko)
IE (1) IE914331A1 (ko)
ZA (1) ZA919695B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728220T2 (de) * 1996-01-31 2005-01-27 Japan Science And Technology Corp., Kawaguchi Antitumormittel mit silizium und stickstoff enthaltenden verbindungen als hauptbestandteil
US6274561B1 (en) 1997-01-29 2001-08-14 Japan Science & Technology Corp. Antitumor agents comprising as the principal compounds containing silicon and nitrogen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ223340A (en) * 1987-02-03 1991-03-26 Merrell Dow Pharma Polyamine derivatives and pharmaceutical compositions
DE69018099T2 (de) * 1989-01-10 1995-08-03 Merrell Dow Pharma Polyamin-Derivate als antineoplastische Mittel.
AU628174B2 (en) * 1989-05-23 1992-09-10 Merrell Dow Pharmaceuticals Inc. A method of potentiating cell-mediated immunity utilizing polyamine derivatives

Also Published As

Publication number Publication date
ATE163264T1 (de) 1998-03-15
ES2113870T3 (es) 1998-05-16
EP0490380B1 (en) 1998-02-18
ZA919695B (en) 1992-09-30
DE69128926D1 (de) 1998-03-26
EP0490380A2 (en) 1992-06-17
IE914331A1 (en) 1992-06-17
DE69128926T2 (de) 1998-06-04
JPH04275233A (ja) 1992-09-30
AU8890791A (en) 1992-06-18
KR100195423B1 (ko) 1999-06-15
DK0490380T3 (da) 1998-09-23
AU648846B2 (en) 1994-05-05
EP0490380A3 (en) 1993-03-10
GR3026432T3 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
HU0301601D0 (en) Bis(n-substituted)-staurosporine derivatives, their use and pharmaceutical composition containing thereof
TR200002243T2 (tr) Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
ATE102838T1 (de) Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel.
KR910019620A (ko) 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료
FI870415A (fi) Terapeutiskt anvaendbara /2,2-bis(aminometyl)-1,3-propandiol-n,n')-platinakomplex och deras framstaellning.
DE69014619D1 (de) Ruthenium(iii)-komplexe als antineoplastische mittel.
KR920011481A (ko) N, n'-비스[3-(에틸아미노)프로필]-1, 7-헵탄디아민 및 세포독성제를 함유하는 암치료용 제약 조성물
DE69223504T2 (de) Bicycloazamakrocyclophosphon-Säure, Komplexe, Konjugate, Kontrastmittel und Herstellung
CA2083148A1 (en) Bistriazenes as chemotherapeutic agents
DE59005456D1 (de) Cytostatische und cytotoxische Wirkstoffkombination zur Anwendung in therapeutischen Verfahren.
KR910016326A (ko) 콜라게나제의 활성화 및 마이엘로페록시다제의 활성을 저해하기 위한 테니댑(Tenidap)의 용도
FR2522968B1 (fr) Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine
ATE28566T1 (de) Zellgiftiges arzneimittel enthaltend mindestens ein immunotoxin und ein amin.
FI895005A0 (fi) Immunotoxiner foer behandling och profylax av autoimmuna sjukdomar.
KR900017599A (ko) 종양 치료용 약학 조성물
ZA913644B (en) 3'-deamino-4'-deoxy-4'-amino-8-fluoroanthracyclines and processes for their preparation
JPS6461429A (en) Remedy for cancer
FR2717814B1 (fr) Dérivés de 1,2,4-triazolo(4,3-a)pyrazine-4-one, leur préparation et les médicaments les contenant.
Ciugudeanu et al. Evaluation of chronic toxicity of morpholine.).
Golberg et al. Myelotoxic action of a new antineoplastic drug spirobramine.
ATE4713T1 (de) 2-oxo-benzothiazolin-, benzoxazolin- oder indolin-derivate, deren herstellung und derartige verbindungen enthaltende pharmazeutische zusammensetzungen.
DE69409633D1 (de) Transdermal behandlung von krebs mit wasserunlöslichem s-camtothecin mit geschlossenem lactoring
ATE8399T1 (de) 1,2,4-triazolo(4,3-a)chinolin-1-(2h)-one und diese verbindungen zur pharmazeutischen verwendung.
CA2235967A1 (en) Diarylethylene metallocene derivatives, their processes of preparation and pharmaceutical compositions containing said derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee